Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis

Yasushi Yamasaki, Kazuhiro Nouso, Koji Miyahara, Nozomu Wada, Chihiro Dohi, Yuki Morimoto, Hideaki Kunugasa, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Maho Amano, Shin Ichiro Nishimura, Kazuhide Yamamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aim: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS). Methods: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined. Results: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis. Conclusion: We clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.

Original languageEnglish
Pages (from-to)528-534
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Fatty Liver
Polysaccharides
Biomarkers
Serum
ROC Curve
Fibrosis
Multivariate Analysis
Odds Ratio

Keywords

  • Diagnosis
  • Non-alcoholic steatohepatitis
  • Serum glycan

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Cite this

Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis. / Yamasaki, Yasushi; Nouso, Kazuhiro; Miyahara, Koji; Wada, Nozomu; Dohi, Chihiro; Morimoto, Yuki; Kunugasa, Hideaki; Takeuchi, Yasuto; Yasunaka, Tetsuya; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Iwasaki, Yoshiaki; Amano, Maho; Nishimura, Shin Ichiro; Yamamoto, Kazuhide.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 30, No. 3, 01.03.2015, p. 528-534.

Research output: Contribution to journalArticle

Yamasaki, Y, Nouso, K, Miyahara, K, Wada, N, Dohi, C, Morimoto, Y, Kunugasa, H, Takeuchi, Y, Yasunaka, T, Kuwaki, K, Ohnishi, H, Ikeda, F, Miyake, Y, Nakamura, S, Shiraha, H, Takaki, A, Iwasaki, Y, Amano, M, Nishimura, SI & Yamamoto, K 2015, 'Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis', Journal of Gastroenterology and Hepatology (Australia), vol. 30, no. 3, pp. 528-534. https://doi.org/10.1111/jgh.12726
Yamasaki, Yasushi ; Nouso, Kazuhiro ; Miyahara, Koji ; Wada, Nozomu ; Dohi, Chihiro ; Morimoto, Yuki ; Kunugasa, Hideaki ; Takeuchi, Yasuto ; Yasunaka, Tetsuya ; Kuwaki, Kenji ; Ohnishi, Hideki ; Ikeda, Fusao ; Miyake, Yasuhiro ; Nakamura, Shinichiro ; Shiraha, Hidenori ; Takaki, Akinobu ; Iwasaki, Yoshiaki ; Amano, Maho ; Nishimura, Shin Ichiro ; Yamamoto, Kazuhide. / Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis. In: Journal of Gastroenterology and Hepatology (Australia). 2015 ; Vol. 30, No. 3. pp. 528-534.
@article{cb95c29fe6ef419a82aed1434a7d7a84,
title = "Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis",
abstract = "Background and Aim: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS). Methods: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined. Results: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis. Conclusion: We clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.",
keywords = "Diagnosis, Non-alcoholic steatohepatitis, Serum glycan",
author = "Yasushi Yamasaki and Kazuhiro Nouso and Koji Miyahara and Nozomu Wada and Chihiro Dohi and Yuki Morimoto and Hideaki Kunugasa and Yasuto Takeuchi and Tetsuya Yasunaka and Kenji Kuwaki and Hideki Ohnishi and Fusao Ikeda and Yasuhiro Miyake and Shinichiro Nakamura and Hidenori Shiraha and Akinobu Takaki and Yoshiaki Iwasaki and Maho Amano and Nishimura, {Shin Ichiro} and Kazuhide Yamamoto",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/jgh.12726",
language = "English",
volume = "30",
pages = "528--534",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis

AU - Yamasaki, Yasushi

AU - Nouso, Kazuhiro

AU - Miyahara, Koji

AU - Wada, Nozomu

AU - Dohi, Chihiro

AU - Morimoto, Yuki

AU - Kunugasa, Hideaki

AU - Takeuchi, Yasuto

AU - Yasunaka, Tetsuya

AU - Kuwaki, Kenji

AU - Ohnishi, Hideki

AU - Ikeda, Fusao

AU - Miyake, Yasuhiro

AU - Nakamura, Shinichiro

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Iwasaki, Yoshiaki

AU - Amano, Maho

AU - Nishimura, Shin Ichiro

AU - Yamamoto, Kazuhide

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background and Aim: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS). Methods: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined. Results: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis. Conclusion: We clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.

AB - Background and Aim: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS). Methods: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined. Results: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis. Conclusion: We clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.

KW - Diagnosis

KW - Non-alcoholic steatohepatitis

KW - Serum glycan

UR - http://www.scopus.com/inward/record.url?scp=84923247058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923247058&partnerID=8YFLogxK

U2 - 10.1111/jgh.12726

DO - 10.1111/jgh.12726

M3 - Article

VL - 30

SP - 528

EP - 534

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 3

ER -